Primary Care Medical Co.

primarycare.sa

Primary Care is a Chain of primary care polyclinics and Retail Pharmacies over Riyadh. Primary Care Co. is one of ReAya holding portfolio companies. ReAya Holding is MENA's first Investment Holding Co. fully dedicated to investments across the whole value chain of Healthcare & Life Sciences sub-sector(s).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BIOCYTOGEN ANNOUNCES COLLABORATION WITH FINEIMMUNE TO DEVELOP TCR-MIMIC ANTIBODY-BASED CELL THERAPY

Biocytogen | September 16, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform. Biocytogen’s TCR-mimic antibody development platform utilizes its pro...

Read More

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

news image

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

news image

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

news image

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More
news image

CELL AND GENE THERAPY

BIOCYTOGEN ANNOUNCES COLLABORATION WITH FINEIMMUNE TO DEVELOP TCR-MIMIC ANTIBODY-BASED CELL THERAPY

Biocytogen | September 16, 2022

Biocytogen Pharmaceuticals Co., Ltd. announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform. Biocytogen’s TCR-mimic antibody development platform utilizes its pro...

Read More
news image

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More
news image

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More
news image

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More